Press   |   April 19, 2019

Dartmouth-Hitchcock Medical Center To Participate in Evaluation of nRichDX Revolution System

(Irvine, CA.  April 19, 2019) – nRichDX Inc. is pleased to confirm that, under the direction of Gregory  J. Tsongalis, PhD, HCLD, CC, Dartmouth-Hitchcock Medical Center will participate in beta studies evaluating the performance of the nRichDX’s liquid biopsy sample prep platform, the Revolution System.  The studies will focus on the System’s ability to deliver greater target yields by combining larger volume processing with high recovery rates.  Dr. Tsongalis is an acknowledged thought leader in the development and implementation of clinical molecular diagnostic technologies.

Update, September 9, 2019

Dartmouth-Hitchcock Medical Center will present the following poster with the results of its Revolution System studies at AMP 2019 in Baltimore, MD (November 7-9, 2019):

Assessment of the nRichDX Revolution™ Instrument and Isolation Kit for Cell-Free DNA Extraction from Liquid Biopsy

Poster #TT044 | Abstract #16939 | Technical Topics category